• About Stallergenes
  • Stallergenes share
  • Financial Calendar
  • Press releases
  • Publications
  • Shareholder area
More details
11.10.07

Quarterly information

 

3rd quarter (Q3) sales up 17%

9-month cumulative sales up 17%

 

 

 

(€ millions)

2007

2006

07/06

 

 

%Sales

 

%Sales

% change

Southern Europe (1)

20.63  

    70.6  

17.61  

    70.7  

17  

Other EU countries (2)

7.07  

    24.2  

6.06  

    24.4  

17  

Other markets

1.51  

      5.2  

1.22  

      4.9  

24  

 

 

 

 

 

 

SLIT

22.13  

    75.8  

18.14  

    72.9  

22  

SCIT

5.96  

    20.4  

5.60  

    22.5  

6  

Other products

1.12  

      3.8  

1.15  

      4.6  

 (3) 

 

 

 

 

 

 

Total Q3 sales

29.21  

  100.0  

24.89  

  100.0  

17  

Southern Europe (1)

77.16  

    74.2  

65.71  

    73.8  

17  

Other EU countries (2)

22.83  

    21.9  

19.78  

    22.2  

15  

Other markets

4.02  

      3.9  

3.60  

      4.0  

      12  

 

 

 

 

 

 

SLIT

81.88  

    78.7  

67.55  

    75.8  

21  

SCIT

17.78  

    17.1  

17.23  

    19.3  

3  

Other products

4.35  

      4.2  

4.31  

      4.8  

1  

 

 

 

 

 

 

9-month cumulated sales 

104.01

  100.0  

89.09  

  100.0  

17  

(1) Portugal, Spain, France, Italy, Greece;

(2) Switzerland included

 

 

 

 

 

 

Sales growth and financial position

2007 3rd quarter sales registered further significant growth in all markets (+17%, vs +9% in 2006).  The most vigorous market segment remained sublingual route desensitization (SLIT, +22%).  Subcutaneous route sales (SCIT) increased by 6%.  Cumulative sales for the first nine months of the year increased by 17% (vs +13% in 2006).

The financial position improved.  Net debt declined 40% from net debt at 30 September 2006.

Significant 3rd quarter transactions and events

The new allergen production facility has been completed.  Collection and validation operations are being implemented within the planned timeframe.

The market authorisation procedure for the ORALAIR® Grasses allergen tablet by the P.E.I. German agency is still ongoing.  Management is confident the procedure will soon be completed.

Outlook for the current year

The Group now provides guidance of 12% to 14% full-year sales growth and profitability close to that of 2006 in absolute value.



Files:
Stallergenes_press_release_-_2007_3rd_Quarter_Sales.pdf
<- Back to: 2007